IRCT20220408054450N1
Completed
Phase 4
To compare the safety and efficacy of Dapagliflozin and Glimepiride as add-on to Metformin in patients with type 2 diabetes.
Bahria University Medical & Dental College0 sites200 target enrollmentTBD
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Bahria University Medical & Dental College
- Enrollment
- 200
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •normal baseline levels of LFT, RFT, lipid profile, and white blood cell count (WBC).
- •The fasting plasma glucose (FBG) levels of all recruited participants to be \= 126 mg/dL
- •hemoglobin A1c levels to be \>7\-10%
- •1500 mg/day metformin monotherapy for last 3 to 6 months.
- •Age of 45\-55 years old
- •Either gender
Exclusion Criteria
- •Hypertension
- •Decompensated or acute congestive heart failure
- •Estimated glomerular filtration rate (egfr) less than 60 ml/min/1\.73 m2
- •Left ventricular ejection fraction (levf) less than 40%
- •Liver impairment
- •Terminal illness, or cancer
- •Unwilling to give consent or participate
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not Yet Recruiting
Phase 4
Effectiveness and Safety of diabetic drugs in diabetic participantsCTRI/2024/07/071196Dr Manu Arya
Not Yet Recruiting
N/A
Dapagliflozin in Heart FailureCTRI/2022/11/047725Sanjay Kumar R
Completed
N/A
Evaluation of efficiency and safety of dapagliflozin in treating of type 2 diabetes mellitustype 2 diabetesJPRN-UMIN000023681Juntendo University Urayasu Hospital30
Not Yet Recruiting
N/A
Benefits and side effects of Dapagliflozin medicine in diabetic patients with kidney disease.CTRI/2022/09/045596Maulana Azad Medical College Delhi
Not Yet Recruiting
N/A
Dapagliflozin is a licensed medicine used for reducing blood sugar in people with diabetes and this study will test whether it can also reduce the stiffness in the liver which commonly occurs in diabetes.Health Condition 1: E116- Type 2 diabetes mellitus with other specified complicationsCTRI/2019/05/019286Dr Shashi Panicker